These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9636541)

  • 21. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
    Vincenti F
    Transplant Proc; 2001 Jun; 33(4 Suppl):11S-18S. PubMed ID: 11406263
    [No Abstract]   [Full Text] [Related]  

  • 22. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP; Nampoory MR; Johny KV; Costandi JN; Abdulhalim M; El-Reshaid W; Al-Muzairai I; Ninan VT; Samhan M; Al-Mousawi M
    Transplant Proc; 2001 Aug; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract]   [Full Text] [Related]  

  • 23. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
    Lácha J; Símová M; Nosková L; Teplan V; Vítko S
    Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
    [No Abstract]   [Full Text] [Related]  

  • 24. New monoclonal antibodies to prevent transplant rejection.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):93-4. PubMed ID: 9774964
    [No Abstract]   [Full Text] [Related]  

  • 25. [Anti interleukin-2 receptor alpha antibodies (daclizumab) application for the treatment of kidney recipients].
    Izvolskaja N; Rainiene T; Dainys B
    Medicina (Kaunas); 2003; 39 Suppl 1():166-70. PubMed ID: 12761441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR; Moudgil A; Vo A; Jordan SC
    Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 28. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract]   [Full Text] [Related]  

  • 29. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
    Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients.
    Abou-Jaoude MM; Ghantous I; Najm R; Afif C; Almawi WY
    Transplant Proc; 2003 Nov; 35(7):2731-2. PubMed ID: 14612096
    [No Abstract]   [Full Text] [Related]  

  • 32. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
    Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
    Abou-Jaoude MM; Ghantous I; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibody approved for renal transplants.
    Am J Health Syst Pharm; 1998 Feb; 55(3):207-8. PubMed ID: 9492247
    [No Abstract]   [Full Text] [Related]  

  • 35. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical effect of induction therapy with monoclonal antibodies after deceased-donor kidney transplantation (an experience from Vilnius Center)].
    Rainiene T; Dobrovolskiene R; Dainys B; Kucinskis G; Zelvys A
    Medicina (Kaunas); 2007; 43 Suppl 1():109-13. PubMed ID: 17551287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
    Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
    Smith JM; Nemeth TL; McDonald RA
    Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunosuppressive treatment options in renal transplantation.
    Ciancio G; Burke GW; Jorge D; Rosen A; Miller J
    Minerva Urol Nefrol; 2005 Sep; 57(3):141-9. PubMed ID: 15986013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.